Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

Source: AP News, June 2019

— ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma — As of the April 5, 2019 data cut-off, five patients treated in the weekly dosing schedule group achieved confirmed responses, one of which was a complete response (CR) — Of the eight TNBC patients evaluable for efficacy, one anti-PD-1 naïve TNBC patient achieved a CR and two anti-PD-1 naïve TNBC patients achieved partial responses (PRs) — Of the 25 melanoma patients radiologically evaluable for efficacy, two previously immunotherapy-treated melanoma patients achieved PRs

BERKELEY, Calif., June 02, 2019 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. Aduro’s ADU-S100 (MIW815), a novel STING pathway activator, is being evaluated in combination with Novartis’ spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody, in patients with advanced solid tumors or lymphomas. The findings were presented as an oral abstract today by Dr. Funda Meric-Bernstam at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (Abstract #2507).

“We are pleased with the clinical progress to date of ADU-S100 in combination with spartalizumab,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “The safety profile and preliminary anti-tumor activity demonstrated in patients with triple-negative breast cancer and other tumor types are encouraging. We look forward to completing dose escalation and evaluating with our partner Novartis the clinical and pharmacodynamic biomarker activity that may provide a basis for advancing this combination therapy toward dose expansion in tumor types where the potential to benefit patients is greatest.”

read the original full article